Travaux

Tous les travaux de la base. Chaque rangée indique les voies par lesquelles le travail a été admis, car une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée.

Voie

Domaine

Type

Langue

Période

Consensus du tri

Ordre

Indicateurs

RétractésSans résumé

Données de dépistage

Source des étiquettes

Catégorie

Plan d’étude

Accord direct

Couverture directe

Les étiquettes directes sont rares et non validées. Une absence reste inconnue.

1 filtre actif

66 travauxpage 1 sur 3

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

2014· article· en· The Lancet Oncology· Biochemistry, Genetics and Molecular Biology

affsans résumé

788

citations

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

2015· article· en· Nature Medicine· Medicine

affsans résumé

711

citations

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

2013· review· en· Leukemia· Medicine

affsans résumé

232

citations

Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes

2014· article· en· PLoS Pathogens· Immunology and Microbiology

afffund

206

citations

Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets

2021· review· en· International Journal of Molecular Sciences· Biochemistry, Genetics and Molecular Biology

aff

180

citations

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations

2019· article· en· PLoS Pathogens· Immunology and Microbiology

fundno aff

157

citations

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

2016· article· en· Blood· Medicine

afffund

140

citations

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

2013· article· en· Cancer Chemotherapy and Pharmacology· Biochemistry, Genetics and Molecular Biology

affsans résumé

citations

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

2017· article· en· Leukemia· Medicine

affsans résumé

citations

A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma

2017· article· en· Oncotarget· Biochemistry, Genetics and Molecular Biology

affabout

citations

Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)

2023· article· en· Neuro-Oncology· Medicine

aff

citations

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

2015· article· en· Leukemia· Biochemistry, Genetics and Molecular Biology

aff

citations

The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

2012· article· en· Seminars in Hematology· Medicine

affsans résumé

citations

Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients

2017· article· en· Neuro-Oncology· Medicine

aff

citations

Histone Deacetylase Inhibitors Dose-Dependently Switch Neutrophil Death from NETosis to Apoptosis

2019· article· en· Biomolecules· Immunology and Microbiology

afffund

citations

Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products

2018· article· en· Viruses· Immunology and Microbiology

afffund

citations

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

2011· article· en· Blood· Medicine

aff

citations

ING1 and 5-Azacytidine Act Synergistically to Block Breast Cancer Cell Growth

2012· article· en· PLoS ONE· Biochemistry, Genetics and Molecular Biology

afffund

citations

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

2014· review· en· Bone Marrow Transplantation· Medicine

affsans résumé

citations

Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma

2021· article· en· Clinical Cancer Research· Biochemistry, Genetics and Molecular Biology

afffund

citations

Development of target‐specific treatments in multiple myeloma

2010· review· en· British Journal of Haematology· Medicine

aff

citations

Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment

2021· article· en· Molecular Cancer Research· Biochemistry, Genetics and Molecular Biology

aff

citations

Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

2018· article· en· Leukemia & lymphoma/Leukemia and lymphoma· Medicine

aff

citations

A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

2013· article· en· Cancer Chemotherapy and Pharmacology· Biochemistry, Genetics and Molecular Biology

affsans résumé

citations

Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy

2021· article· en· Cancers· Biochemistry, Genetics and Molecular Biology

aff

citations